HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05036811

Acronym

MAIVIH

Enrollment

400

Registered

2021-09-08

Start date

2021-06-07

Completion date

2023-03-31

Last updated

2021-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hiv

Brief summary

Follow-up registry of patients living with HIV who also have various inflammatory and autoimmune pathologies that may require immunosuppressive treatment.

Interventions

OTHERdata collection

data collection

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patient living with HIV * Carrier of one or more of the following diseases: Sarcoidosis Multiple sclerosis Myasthenia gravis Crohn's disease Hemorrhagic rectocolitis Autoimmune hepatitis Arthropathic psoriasis Still's disease, other rheumatoid arthritides, juvenile polyarthritides, Rheumatoid arthritis Vasculitides: periarteritis nodosa and related conditions, other necrotizing vasculopathies (periarteritis nodosa, juvenile periarteritis, Churg-Strauss disease, polyangiitis, Kawasaki disease, Horton's disease, Wegener's disease, thrombotic microangiopathy, Takayashu syndrome, Good-Pasture's syndrome, thrombocytopenic purpura) Lupus Polymyositis or dermatopolymyositis Connectivitis (Behcet's disease, Gougerot-Sjöogren syndrome) Inflammatory spondyloarthropathies (APS, spondyloarthritis, other spondyloarthropathies)

Exclusion criteria

* Opposition of the person * Minor patients * Patients under judicial protection

Design outcomes

Primary

Measure	Time frame
Number of patients living with HIV who have an inflammatory or autoimmune disease	At the end of the study an average of 18 months

Secondary

Measure	Time frame
Number of patients on immunosuppressive treatment,	At the end of the study an average of 18 months
Occurrence of infectious complications	At the end of the study an average of 18 months
Number of patients on remission	At the end of the study an average of 18 months
Evolution of CD4 and HIV viral load	At the end of the study an average of 18 months

Countries

France

Contacts

Primary ContactNathalie VIGET, MD

nviget@ch-tourcoing.fr0320694848

Backup ContactSolange TREHOUX, PhD

strehoux@ch-tourcoing.fr0320694280

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026